| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
JG-2016 targets histone acetyltransferase 1 (HAT1), an enzyme that catalyzes the transfer of acetyl groups from acetyl-CoA to histone proteins, particularly histone H4. HAT1 plays a critical role in chromatin assembly and regulation of gene expression through histone acetylation. By inhibiting HAT1 activity, JG-2016 modulates the acetylation status of histones, thereby affecting chromatin structure and transcriptional programs that are important for cell proliferation, differentiation, and survival.
|
|---|---|
| ln Vitro |
In vitro, JG-2016 demonstrates potent inhibition of HAT1 with an IC₅₀ of 14.8 μM in HAT1 acetylation assays. The compound's activity is assessed using biochemical assays that measure the transfer of acetyl groups from acetyl-CoA to histone substrates. The IC₅₀ value indicates the concentration required to inhibit 50% of HAT1 enzymatic activity, demonstrating that JG-2016 is an effective inhibitor of this histone acetyltransferase.
|
| ln Vivo |
In vivo activity data for JG-2016 are limited at this time. As a potent inhibitor of HAT1 with a role in epigenetic regulation, the compound is expected to demonstrate biological effects in animal models of cancer and other diseases where HAT1 plays a pathogenic role. Typical in vivo studies for HAT1 inhibitors involve administration to tumor-bearing mouse models to assess antitumor efficacy and evaluation of histone acetylation markers in target tissues.
|
| Enzyme Assay |
For non-cellular in vitro enzyme/receptor binding assays, JG-2016 is evaluated for its HAT1 inhibitory activity using purified HAT1 enzyme. The compound is incubated with HAT1, acetyl-CoA, and a histone substrate (such as histone H4 or a peptide derived from it). The incorporation of acetyl groups into the substrate is measured using radioactive labeling, fluorescence, or antibody-based detection methods. The inhibitory activity is quantified by comparing the acetylation levels in the presence versus absence of the compound, allowing determination of the IC₅₀.
|
| Cell Assay |
For in vitro cellular assays, JG-2016 is tested in various cell lines to assess its effects on histone acetylation and cell proliferation. Cells are treated with serial dilutions of the compound, and histone acetylation levels are measured by Western blot using acetylation-specific antibodies. Cell viability and proliferation are assessed using standard assays such as MTT, CCK-8, or CellTiter-Glo. Additional assays may include assessment of gene expression changes by qPCR or RNA-seq to identify downstream targets of HAT1 inhibition.
|
| Animal Protocol |
For in vivo animal studies, JG-2016 would typically be evaluated in mouse models of cancer or other diseases where HAT1 is implicated. The compound can be formulated for intraperitoneal or oral administration using vehicles such as DMSO:Tween 80:Saline (10:5:85). Tumor-bearing mice are treated with the compound at various doses, and tumor growth, histone acetylation markers, and survival are assessed. Body weight and general health are monitored to evaluate tolerability.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for JG-2016 are limited. As a small-molecule inhibitor with a molecular weight of 376.84, it is expected to have moderate oral bioavailability. The compound is soluble in DMSO and can be formulated for in vivo administration. Powder can be stored at -20°C for up to 3 years, and stock solutions in solvent can be stored at -80°C for 6 months or at -20°C for 1 month. The compound is stable at ambient temperature for a few days during shipping. Further pharmacokinetic studies would be needed to fully characterize its ADME profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for JG-2016 are limited. As a HAT1 inhibitor that modulates epigenetic regulation, the compound may have dose-dependent effects on normal cellular functions. Comprehensive toxicology studies including acute and repeat-dose toxicity, genotoxicity, and organ-specific toxicity assessments would be required for therapeutic development. The compound is for research use only and not for human use.
|
| References | |
| Additional Infomation |
JG-2016 is a potent inhibitor of histone acetyltransferase 1 (HAT1) with an IC₅₀ of 14.8 μM in HAT1 acetylation assays. The compound is designed to modulate epigenetic regulation in cancer and stem cell biology. As a HAT1 inhibitor, JG-2016 represents a valuable tool for studying the role of histone acetylation in gene expression regulation and for validating HAT1 as a therapeutic target in cancer and other diseases. The compound has a molecular formula of C₁₈H₂₁ClN₄O₃ and a molecular weight of 376.84.
|
| Molecular Formula |
C18H21CLN4O3
|
|---|---|
| Molecular Weight |
376.837342977524
|
| Exact Mass |
376.13
|
| CAS # |
2887480-87-5
|
| PubChem CID |
166558326
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
634
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC1=CC2=C(C=C1Cl)N=C3C(=O)NC(=O)N=C3N2CCOCC(C)C
|
| InChi Key |
IOHJEWFKBRNJIO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H21ClN4O3/c1-4-11-7-14-13(8-12(11)19)20-15-16(21-18(25)22-17(15)24)23(14)5-6-26-9-10(2)3/h7-8,10H,4-6,9H2,1-3H3,(H,22,24,25)
|
| Chemical Name |
7-chloro-8-ethyl-10-[2-(2-methylpropoxy)ethyl]benzo[g]pteridine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6536 mL | 13.2682 mL | 26.5365 mL | |
| 5 mM | 0.5307 mL | 2.6536 mL | 5.3073 mL | |
| 10 mM | 0.2654 mL | 1.3268 mL | 2.6536 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
